Zota Health Care Limited (NSE: ZOTA) has successfully received product registration licenses for twelve of its pharmaceutical products from the Department of Pharmaceutical Administration, Vietnam. This marks a significant step in the company’s expansion into the Vietnamese market. The approved products include a variety of therapeutic categories such as angiotensin II antagonists, NSAIDs, antibiotics, and anti-hyperlipidemic agents, positioning the company to meet the growing demand for diverse healthcare solutions in the region.
Among the twelve products granted licenses, well-known drugs like Telmisartan, Etoricoxib, Levofloxacin, and Rosuvastatin are included. These products have been approved for a validity period of five years, with the possibility of renewal after the expiration period. The company plans to begin exporting these products to Vietnam in the near future, further strengthening its international footprint.
The registration of these products is a testament to Zota Health Care’s commitment to expanding its global presence and meeting the evolving healthcare needs of international markets. The company aims to capitalize on this achievement by introducing its broad portfolio to the Vietnamese market, where the demand for high-quality pharmaceutical products continues to rise.
Zota Health Care’s successful entry into Vietnam underscores the company’s ongoing strategy to diversify its global operations and ensure the availability of advanced healthcare solutions worldwide.
